Evaluation of Health Care Resource Utilization and Costs Among Bio Naïve Crohn’s Disease Patients Initiating Biologics with Two Years of Follow-up
Author(s)
Cyhaniuk A1, Zhao R2, Ding Z3, Gupta P1, Kachroo S2
1STATinMED Research, Plano, TX, USA, 2Janssen Scientific Affairs, LLC, Horsham, PA, USA, 3Janssen Scientific Affairs, LLC, Furlong, PA, USA
Presentation Documents
Objective: This study examined Crohn’s Disease (CD)-related health care resource utilization (HCRU) and costs among bio-naïve CD patients initiating biologics over a 2-year follow-up period.
Methods: This descriptive study used claims data pooled from Optum Clinformatics (09/2015 – 02/2020), IBM MarketScan (09/2015 – 09/2019), and IQVIA PharMetrics (09/2015 – 02/2020) databases. Adult patients with ≥1 CD medical claim and ≥1 medical/pharmacy claim for adalimumab [ADA], ustekinumab [UST], and vedolizumab [VDZ] were selected. Index date was the first biologic claim date. Patients had continuous eligibility for ≥12 months pre (baseline) and ≥24 months post index date (follow-up). Only bio-naïve patients were included as patients with no prior biologic usage in the baseline. Using a claims-based algorithm, confirmed CD patients were included in the final cohort. CD-related HCRU and costs were descriptively examined and reported.
Results: A total of 1,735 bio-naïve CD patients were identified (161 [9.3%] UST, 232 [13.4%] VDZ, and 1,342 [77.3%] ADA). Compared to baseline, proportion of patients with CD-related inpatient stays decreased for UST (27.3% vs 16.2%), VDZ (22.4% vs 11.6%), and ADA (13.0% vs 5.0%) in the second year post biologic initiation. Numerically, the mean annual CD-related inpatient costs decreased by $5,917 for UST, by $698 for VDZ, and by $4,878 for ADA in the second year of follow-up from baseline. Proportion of patients with CD-related ER visits decreased numerically for UST (21.7% baseline to 16.2% second year of follow-up), VDZ (19.4% vs 13.8%) and ADA (11.9% to 6.9%). Numerical decreases were also observed for CD-related ER costs.
Conclusions: Among bio-naïve CD patients who initiated biologics, numerically there was a decrease in the proportion of patients with CD-related ER visits, inpatient stays, and associated costs from baseline to the second year of follow-up.
Conference/Value in Health Info
2022-05, ISPOR 2022, Washington, DC, USA
Value in Health, Volume 25, Issue 6, S1 (June 2022)
Code
EE281
Topic
Economic Evaluation
Disease
Gastrointestinal Disorders
Your browser is out-of-date
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now